GlassScriptPhysician profile
Kassandra B Cunningham
NPI 1477724672
$3,923.47
in general payments reported to CMS, 2019-2025
26 companies · $762 in 2025
The $762 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $814 · 2023: $963 · 2024: $775 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $716.38 | 2021-2025 | |
| Amgen INC. | $418.84 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.25 | 2021-2025 | Jardiance |
| Pfizer INC. | $407.71 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $295.29 | 2022-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $268.85 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $235.17 | 2021-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $223.62 | 2021-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $165.44 | 2021-2024 | |
| Novo Nordisk INC | $124.60 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Heartflow, INC. | $115.23 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $82.80 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $59.66 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $57.04 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $56.30 | 2023-2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $52.48 | 2023-2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $41.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.06 | 2022-2025 | |
| Edwards Lifesciences Corporation | $32.72 | 2025 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $27.50 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $21.45 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $20.39 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.31 | 2023 | Quviviq |
| Kiniksa Pharmaceuticals, LTD. | $13.03 | 2023 | Arcalyst |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassandra Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.